Scott Markham, DO
Family Medicine · Harlan, IANPI 1700994308
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$702
- Lilly USA, LLC$561
- AstraZeneca$453
- Novartis$435
- Amgen$406
- Pfizer$346
- plus $2K from 34 others
Across 39 payments — averaging $185.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$7K
What the payments were for
- Food & beverage$5,172100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 48 | $702 |
| Lilly USA, LLC | 36 | $561 |
| AstraZeneca(2 entities) | 29 | $453 |
| Novartis | 25 | $435 |
| Amgen | 27 | $406 |
| Pfizer | 25 | $346 |
| Bayer | 17 | $300 |
| Boehringer Ingelheim | 13 | $233 |
| Johnson & Johnson(2 entities) | 14 | $191 |
| Merck | 10 | $147 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $125 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $117 |
| Biohaven Pharmaceuticals, Inc. | 4 | $89 |
| Amarin Pharma, Inc. | 3 | $68 |
| Vertex | 4 | $61 |
| E.r. Squibb & Sons, L.L.C. | 5 | $57 |
| VBI Vaccine (delaware) Inc. | 3 | $56 |
| AbbVie | 3 | $56 |
| Genentech USA, Inc. | 3 | $48 |
| Abbott | 2 | $46 |
| Currax Pharmaceuticals LLC | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| GSK | 3 | $42 |
| Mylan Specialty L.p. | 3 | $41 |
| Eisai Inc. | 2 | $39 |
| Bioxcel Therapeutics, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $34 |
| Exact Sciences | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Biogen | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Organogenesis Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Medtronic | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
How this compares
$5,183 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $118,154 |
| OzempicSemaglutide | 70 | $77,965 |
| JardianceEmpagliflozin | 78 | $59,599 |
| MounjaroTirzepatide | 48 | $50,463 |
| TrulicityDulaglutide | 50 | $49,324 |
| XareltoRivaroxaban | 82 | $44,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,769 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $16,237 |
| FarxigaDapagliflozin Propanediol | 12 | $14,078 |
| EntrestoSacubitril/Valsartan | 20 | $12,095 |
| LinzessLinaclotide | 22 | $11,262 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,922 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $9,068 |
| ExelonRivastigmine | 12 | $8,096 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $118,154187 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $561 | $101,026115 claims |
| Novo NordiskOzempic | $702 | $77,96570 claims |
| Boehringer IngelheimJardiance | $233 | $59,59978 claims |
| Johnson & JohnsonXarelto | $191 | $44,07582 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $42 | $34,69058 claims |
| NovartisEntresto, Exelon | $435 | $20,19132 claims |
| AstraZenecaFarxiga | $453 | $14,07812 claims |
| AbbVieLinzess | $56 | $11,26222 claims |
| MerckJanumet | $147 | $4,77019 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,972348 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Harlan
- Kirk PetersonHuxley$576K
- Nicholas GoetschWaterloo$525K
- Stephen HarrisonClinton$249K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
- Leslie George PaulsenMuscatine$136K
- Dylan LoweDes Moines$105K
- Michael AbouassalyWest Burlington$88K
- Kevin DeregnierWinterset$68K
- Laura MoellerAmes$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.